Epigenetic silencing of DSC3 is a common event in human breast cancer

被引:89
作者
Oshiro, MM
Kim, CJ
Wozniak, RJ
Junk, DJ
Muñoz-Rodríguez, JL
Burr, JA
Fitzgerald, M
Pawar, SC
Cress, AE
Domann, FE
Futscher, BW [1 ]
机构
[1] Univ Arizona, Arizona Canc Ctr, Dept Pharmacol, Tucson, AZ 85721 USA
[2] Univ Arizona, Arizona Canc Ctr, Dept Toxicol, Tucson, AZ USA
[3] Univ Arizona, Arizona Canc Ctr, Dept Surg, Tucson, AZ USA
[4] Univ Arizona, Arizona Canc Ctr, Dept Cell Biol & Anat, Tucson, AZ USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Iowa City, IA USA
来源
BREAST CANCER RESEARCH | 2005年 / 7卷 / 05期
关键词
D O I
10.1186/bcr1273
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Desmocollin 3 (DSC3) is a member of the cadherin superfamily of calcium-dependent cell adhesion molecules and a principle component of desmosomes. Desmosomal proteins such as DSC3 are integral to the maintenance of tissue architecture and the loss of these components leads to a lack of adhesion and a gain of cellular mobility. DSC3 expression is down-regulated in breast cancer cell lines and primary breast tumors; however, the loss of DSC3 is not due to gene deletion or gross rearrangement of the gene. In this study, we examined the prevalence of epigenetic silencing of DSC3 gene expression in primary breast tumor specimens. Methods We used bisulfite genomic sequencing to analyze the methylation state of the DSC3 promoter region from 32 primary breast tumor specimens. We also used a quantitative real-time RT-PCR approach, and analyzed all breast tumor specimens for DSC3 expression. Finally, in addition to bisulfite sequencing and RT-PCR, we used an in vivo nuclease accessibility assay to determine the chromatin architecture of the CpG island region from DSC3-negative breast cancer cells lines. Results DSC3 expression was downregulated in 23 of 32 (72%) breast cancer specimens comprising: 22 invasive ductal carcinomas, 7 invasive lobular breast carcinomas, 2 invasive ductal carcinomas that metastasized to the lymph node, and a mucoid ductal carcinoma. Of the 23 specimens showing a loss of DSC3 expression, 13 (56%) were associated with cytosine hypermethylation of the promoter region. Furthermore, DSC3 expression is limited to cells of epithelial origin and its expression of mRNA and protein is lost in a high proportion of breast tumor cell lines (79%). Lastly, DNA hypermethylation of the DSC3 promoter is highly correlated with a closed chromatin structure. Conclusion These results indicate that the loss of DSC3 expression is a common event in primary breast tumor specimens, and that DSC3 gene silencing in breast tumors is frequently linked to aberrant cytosine methylation and concomitant changes in chromatin structure.
引用
收藏
页码:R669 / R680
页数:12
相关论文
共 45 条
[1]  
ARNEMANN J, 1993, J CELL SCI, V104, P741
[2]  
Bachman KE, 1999, CANCER RES, V59, P798
[3]  
Baylin SB, 1998, ADV CANCER RES, V72, P141
[4]   The UMD-p53 database:: New mutations and analysis tools [J].
Béroud, C ;
Soussi, T .
HUMAN MUTATION, 2003, 21 (03) :176-181
[5]   Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer [J].
Bianco, T ;
Chenevix-Trench, G ;
Walsh, DCA ;
Cooper, JE ;
Dobrovic, A .
CARCINOGENESIS, 2000, 21 (02) :147-151
[6]   NORMAL KERATINIZATION IN A SPONTANEOUSLY IMMORTALIZED ANEUPLOID HUMAN KERATINOCYTE CELL-LINE [J].
BOUKAMP, P ;
PETRUSSEVSKA, RT ;
BREITKREUTZ, D ;
HORNUNG, J ;
MARKHAM, A ;
FUSENIG, NE .
JOURNAL OF CELL BIOLOGY, 1988, 106 (03) :761-771
[7]  
Chidgey MAJ, 1997, DEV DYNAM, V210, P315, DOI 10.1002/(SICI)1097-0177(199711)210:3<315::AID-AJA11>3.3.CO
[8]  
2-A
[9]   CLONING AND SEQUENCE-ANALYSIS OF DESMOSOMAL GLYCOPROTEIN-2 AND GLYCOPROTEIN-3 (DESMOCOLLINS) - CADHERIN-LIKE DESMOSOMAL ADHESION MOLECULES WITH HETEROGENEOUS CYTOPLASMIC DOMAINS [J].
COLLINS, JE ;
LEGAN, PK ;
KENNY, TP ;
MACGARVIE, J ;
HOLTON, JL ;
GARROD, DR .
JOURNAL OF CELL BIOLOGY, 1991, 113 (02) :381-391
[10]   Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors [J].
Costa, FF ;
Verbisck, NV ;
Salim, ACM ;
Ierardi, DF ;
Pires, LC ;
Sasahara, RM ;
Sogayar, MC ;
Zanata, SM ;
Mackay, A ;
O'Hare, M ;
Soares, F ;
Simpson, AJG ;
Camargo, AA .
ONCOGENE, 2004, 23 (07) :1481-1488